The Influence of AA29504 on GABA Receptor Ligand Binding Properties and Its Implications on Subtype Selectivity
Neurochemical Research, ISSN: 1573-6903, Vol: 47, Issue: 3, Page: 667-678
2022
- 1Citations
- 3Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
The unique pharmacological properties of δ-containing γ-aminobutyric acid type A receptors (δ-GABARs) make them an attractive target for selective and persistent modulation of neuronal excitability. However, the availability of selective modulators targeting δ-GABARs remains limited. AA29504 ([2-amino-4-(2,4,6-trimethylbenzylamino)-phenyl]-carbamic acid ethyl ester), an analog of K channel opener retigabine, acts as an agonist and a positive allosteric modulator (Ago-PAM) of δ-GABARs. Based on electrophysiological studies using recombinant receptors, AA29504 was found to be a more potent and effective agonist in δ-GABARs than in γ2-GABARs. In comparison, AA29504 positively modulated the activity of recombinant δ-GABARs more effectively than γ2-GABARs, with no significant differences in potency. The impact of AA29504's efficacy- and potency-associated GABAR subtype selectivity on radioligand binding properties remain unexplored. Using [H]4'-ethynyl-4-n-propylbicycloorthobenzoate ([H]EBOB) binding assay, we found no difference in the modulatory potency of AA29504 on GABA- and THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol)-induced responses between native forebrain GABARs of wild type and δ knock-out mice. In recombinant receptors expressed in HEK293 cells, AA29504 showed higher efficacy on δ- than γ-GABARs in the GABA-independent displacement of [H]EBOB binding. Interestingly, AA29504 showed a concentration-dependent stimulation of [H]muscimol binding to γ-GABARs, which was absent in δ-GABARs. This was explained by AA29504 shifting the low-affinity γ-GABAR towards a higher affinity desensitized state, thereby rising new sites capable of binding GABAR agonists with low nanomolar affinity. Hence, the potential of AA29504 to act as a desensitization-modifying allosteric modulator of γ2-GABARs deserves further investigation for its promising influence on shaping efficacy, duration and plasticity of GABAR synaptic responses.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85118393025&origin=inward; http://dx.doi.org/10.1007/s11064-021-03475-y; http://www.ncbi.nlm.nih.gov/pubmed/34727270; https://link.springer.com/10.1007/s11064-021-03475-y; https://dx.doi.org/10.1007/s11064-021-03475-y; https://link.springer.com/article/10.1007/s11064-021-03475-y
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know